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1. Introduction 
The term acute phase response (APR) refers to the inflammatory response of the host 
occurring shortly after the tissue injury. It comprises a wide variety of reactions started by 
different causes, like infection, tissue injury, burn, trauma, surgery, cancer or immunological 
disorders. These reactions aim to prevent ongoing tissue damage, isolate and eliminate the 
cause of the inflammation, and begin the repair process necessary to restore the normal 
function. Usually, the local response is accompanied by a systemic reaction characterized by 
the fast alteration of the concentrations of several plasmatic proteins, the APPs (Acute Phase 
Proteins) produced by the liver (Baumann & Gauldie, 1994). In some diseases, the persistent 
immunological activation can cause chronic inflammation, often with pathological 
consequences. In other words, APR is a physiological condition occurring at the beginning 
of the inflammatory process and it is independent of the inflammation origin. 
1.1 The inflammatory response 
The inflammation is the ordered process mediated by the appearance of intercellular 
adhesion molecules on endothelia, and various inflammatory mediators released by tissue 
cells and leucocytes in response to tissue aggression; it is a protective response to injury or 
destruction of tissues, which serves to destroy, dilute, or wall off both the injurious agent 
and the injured tissues. It is the first reaction of the body under a situation of immunological 
stress: the innate non-specific response preceding specific immune reactions. 
The term inflammation is purely descriptive and originally defined by the four Latin words 
dolor, rubor, calor and tumor (meaning pain, redness, warmth and swelling); these are the 
result of changes in the local blood vessels which in turn, lead to their dilatation and 
increased stickiness and permeability for passing leukocytes. Combined, the cell and fluid 
leakage into the tissue, as well as their local activities, account for the pain and swelling. The 
function of this inflammatory response is to bring serum molecules and immune cells to the 
damaged zone. In this response three principal components can be considered: i) increased 
blood supply, ii) increased capillary permeability and, iii) migration of cells out of the 
vessels and into the tissues. 
In an inflammatory reaction there are implicated several cells of the immunological system 
and a great variety of response mediators. The uncontrolled migration of different 
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leukocytes populations would make impossible the generation and control of the immune 
response. In this setting, the endothelium plays a key role. Endothelial cells are 
multifunctional cells that form a thin layer in the interior surface of blood vessels (Cines et 
al., 1998). They are responsible for maintaining the vascular homeostasis but, also, they are 
capable of secreting biologically active mediators when affected by infection, stress, 
hypertension, dyslipidemia or high homocysteine levels. The primary essential function of 
these endothelial cells is to regulate the permeability of the blood vessel and the exchange of 
fluids and cells between the blood and the surrounding tissue. In the inflammatory response 
they raise the expression of cell adhesion molecules that, therefore, increments the number 
of leukocytes binding endothelium (Pate et al., 2010). The increased permeability of the 
endothelium allows the migration of these cells, a process called extravasation, where they 
will exert its function. That is why they are so important for the recruitment and 
orchestration of an acute inflammatory response. 
The role of the different cells and different interactions has been extensively described 
(Imhof & Aurrand-Lions, 2004; Langer & Chavakis, 2009; Ley et al., 2007; Schenkel et al., 
2004; Vestweber, 2007), but briefly we are going to comment those. Normally, neutrophils 
are the first cells to appear at acute phase response, followed by macrophages (monocytes), 
lymphocytes (if there is an immunological challenge) and a small amount of basophils and 
eosinophils; if an extreme vascular leakage occurs, red blood cells may also be found. We 
can distinguish three steps for the migration of cell to the tissue during the inflammatory 
response (Butcher, 1991):  
1-Receptor-mediated recruitment and adhesion to the endothelial cells: the regulation of the 
expression of selectin-P and selectin-E by the endothelium is key in this process (Lasky, 
1995; Lawrence & Springer, 1991). The expression of P-selectin is increased by inflammatory 
molecules such as histamine and thrombine, it is a weak binder to the leukocytes but causes 
them to “slow” their movement in the vessel. Selectin-E expression, on the other hand, it is 
upregulated by cytokines produced by injured cells, such as IL-1 and TNF-; these cytokines 
also activate and increase the expression of integrins on the circulating leukocytes. Activated 
leukocytes, therefore, increase the affinity of their integrins for certain ligands on the 
endothelial surface, attaching them firmly to the endothelium. 
2- Transmigration, or the movement of the activated leukocytes through the endothelium to 
reach the damaged tissue: the leukocytes adhered to the endothelium are stimulated by the 
chemokine gradient to move between the endothelial cells and across the basal membrane to 
the damaged area. Among the chemotactic factors we can find: i) products  of the 
complement like C3a, C4a, C5a (Hartmann et al., 1997; Okusawa et al., 1988), ii) fibrin 
degradation products (FDPs) like the D-dimer (Gross et al., 1997), iii) prostaglandins (PGD2, 
PGE2) (Konya et al., 2010; Kuehn et al., 2011), iv) leukotrienes (LTB4) (Aked & Foster, 1987) 
and chemokines like CCL5 (Kawai et al., 1999; Murooka et al., 2008) and IL-8 (Huber et al., 
1991). 
3- Movement of the activated leukocytes through the tissue: the binding to extracellular 
matrix proteins through the integrins and the CD44 protein allows these cells to arrive to the 
origin of the inflammation following the chemokine gradient (Kinashi, 2005).  
1.1.1 The Pro-inflammatory cytokines 
But in this local inflammatory process, activated leukocytes are not passive: in turn, they 
release cytokines and other mediators like glucocorticoids into the bloodstream, thus 
eliciting a widespread reaction in the organism. There are at least 15 cytokines known to be 
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involved in this process. Some of them are positive/negative regulators of cell growth (IL-2, 
IL-3, IL-4, IL-7, IL-10, IL-11, IL-12 and GM-CSF), while others have got pro-inflammatory 
(TNF-┙/┚, IL-1┙/┚, IL-6, IFN-┙/┛, IL-8) or anti-inflammatory activities (IL-1 antagonists, 
soluble IL-1R, IL-1 and TNF-┙ binding protein)(van Miert, 1995).   
Proinflammatory cytokines, released mainly by activated macrophages, are crucial for the 
induction of other cytokines (IL-6, IL-8), while agents such as platelet activating factor, 
prostaglandins, leukotrienes and nitric oxide increase the chemotactic gradient and 
therefore the leukocyte recruitment to the inflammation site. They are also responsible for 
the fever and catabolism of muscle proteins through their action at the CNS level: We will 
briefly comment some carachteristics of the proinflammatory cytokines involved in the 
acute phase reaction and the production of APPs: 
- Tumor necrosis factor-alpha (TNF-┙) 
TNF-┙ is the main cytokine that mediates acute inflammation. TNF is produced by 
monocytes, macrophages, dendritic cells, Th1 cells, and other cells. Some of its functions 
include: to stimulate the cells from the endothelium to produce selectins and the leukocytes 
to express integrins, to activate the coagulation pathway, to increase the production of 
chemokines in endothelial cells and macrophages, to activate neutrophils and their killer 
activity, etc (Baud & Karin, 2001). It is also responsible for stimulating the liver to produce 
APPs (Xanthoulea et al., 2004), and acting on muscles (Collins & Grounds, 2001) and fat (Lu 
et al., 2006; Plomgaard et al., 2008; Rydén et al., 2002) to stimulate catabolism for energy 
conversion. In addition, it interacts with the hypothalamus to induce lack of appetite 
(Tracey et al., 1990), fever (Rothwell & Hopkins, 1995; Stefferl et al., 1996) and sleep (Deboer 
et al., 2002; Fang et al., 1997). It also participates in the cicatrization process through the 
stimulation of collagen and collagenase synthesis (Theiss et al., 2005).  
-Interleukin-1 (IL-1) 
IL-1 function is similar to TNF- as it also mediates acute inflammatory responses, and 
together they enhance the inflammatory response (Dinarello & Wolff, 1993; Vassalli, 1992). 
Monocytes, macrophages, dendritic cells and endothelial cells are the main sources of IL-1. 
Functions of IL-1 include the promotion of the inflammation through the activation of the 
coagulation pathway and the synthesis of adhesion factors on endothelial cells and 
leukocytes (Bevilacqua et al., 1984; Nawroth et al., 1986) and the activation of macrophages 
(Dinarello, 1988). It is also responsible for stimulating the liver to produce APPs (Baumann 
& Gauldie, 1994; Mortensen et al., 1988; Prowse & Baumann, 1989), for activating the 
catabolism of the fat tissue for energy conversion (Feingold et al., 1992; Tocco-Bradley et al., 
1987); and for regulating the synthesis of collagen and collagenase for scar tissue formation 
(Duncan & Berman, 1989; Mizel et al., 1981).  
It is also noteworthy the role that IL-1 plays in the induction of the fever and sleep (Krueger 
et al., 1984; Opp & Krueger, 1991), as well as the stimulatory effect of IL-1 on the pituitary-
adrenal axis in the CNS (Besedovsky et al., 1986; Sapolsky et al., 1987), thus making it 
responsible for the control of food intake (Luheshi et al., 1999) during the acute phase 
response.   
Interleukin-1 and TNF- have also being linked to the depression and sickness behaviour 
associated to the inflammatory response (Dantzer, 2001; Konsman et al., 2002). One theory 
behind this effect it is the role of IL-1 over serotoninergic neurons, where IL-1 could activate 
the serotonin transporter directly. This could lead to the removal of serotonin from the 
synaptic cleft, thus generating a serotoninergic deprivation signal together with the 
tryptophan deprivation derived from the APPs production (Leonard & Song, 1999).   
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- Interleukin-6 (IL-6) 
IL-6 stimulates the liver to produce APPs and it is released by many cells including T-
lymphocytes, macrophages, monocytes, endothelial cells, and fibroblasts (Prowse & 
Baumann, 1989). It is also responsible for the proliferation stimulation of B-lymphocytes 
(Muraguchi et al., 1988; Taga et al., 1987) and increases the neutrophil activity (Brom & 
König, 1992).  
The outcome of the inflammation will depend on the tissue as well as the extent of injury 
and the injurious agent that has caused it. Usually, the resolution will bring the inflamed 
tissue to its status prior to the injury but, some times, the inflammation is not resolved 
properly. Sometimes a persistent damage or an incomplete resolution process can produce a 
chronic inflammation due to the continuous production of pro-inflammatory cytokines. 
Often, the reason behind the abnormal inflammatory response is not known, and it is the 
reason behind many human diseases. Some of them have got an immunological origin like 
the allergic reactions or myopathies (Lundberg & Grundtman, 2008); but sometimes the 
origin is non-immunological like in rheumatoid arthritis, cancer (Coussens & Werb, 2002), 
atherosclerosis (Libby, 2002), ischaemic heart disease (Maseri et al., 1996), inflammatory 
bowel diseases (Fiocchi, 1998), etc (many articles, reviews and books cover these topics, so 
this is not an extensive list). In all of the above mentioned disorders we can also see 
alterations in the levels of different APPs produced by the liver; the next section will present 
an extensive list of these proteins, where the main characteristics of the different groups will 
be commented briefly.  
2. Acute phase proteins 
APPs is a group of plasma proteins whose concentration varies in response to inflammation 
(Baumann & Gauldie, 1994). They are synthesized mainly by the liver but also by other cell 
types (monocytes, endothelial cells, fibroblasts and adipocytes). According to the variations 
in the concentration of these proteins they can be classified in positive APPs, those that 
increase the concentration, and negative APPs, those that show decreased concentrations 
upon the inflammatory response. There are also other sub-classifications for the positive 
APPs, according to the variation in concentration: Group I positive APPs increase up to 50% 
(ceruloplasmin and complement factor-3 (C3)), Group II from 2 to 5 times (haptoglobin, 
fibrinogen, ┙-globulins with antiprotease-activity and lipopolysaccharide binding protein), 
and Group III from 5 to more than 1000 times (CRP and SAA) (Dowton & Colten, 1988). 
There is a lot of diversity regarding the timings that each of these proteins show any 
variation on its levels. Some proteins alter their levels as soon as 4 h, while others can take 
up to 24 h or even days. CRP (C-reactive protein) and SAA (serum amyloid A) are some of 
these very rapidly increasing proteins: they elevate their levels within the first 4 h after 
tissue injury, opposite to the lipopolysaccharide binding protein, that requires at least 8 h, or 
the serum alpha-l-acid glycoprotein, that needs 48 h. Some of these proteins remain elevated 
for various days, while other only for few hours. The origin behind the inflammation is also 
important: the plasma fibrinogen shows a peak in the concentration at 24 h-48 h or at 96 h, 
depending on the inflammatory stimulus (Colley et al., 1983; Gruys et al., 2005) 
As commented before TNF-, IL-1, and IL-6 are the main cytokines involved in the 
hepatocytic secretion of APPs, but there are many others. Indeed, all type of combinatorial 
effects can regulate the hepatocytic secretion of an APP (addition, synergy, antagonism).  IL-
1 and IL-6 have been used to classify APPs into two subgroups: Type 1 requires the 
www.intechopen.com
 Acute Phase Proteins as Biomarkers of Disease: From Bench to Clinical Practice 
 
131 
synergistic effect of both interleukins for maximum synthesis (examples: CRP, SAA, Alpha-
1-acid glycoprotein 1); type 2 are those that only require IL-6 and usually IL-1 acts 
suppressing more than enhancing its production (examples: fibrinogen chains, haptoglobin, 
alpha-2-Macroglobulin (Ramadori & Christ, 1999)). There are some cytokines that regulate 
the expression of one or two APPs, like Activin A, a cytokine related with the superfamily of 
TGF-┚. On the other hand, other APPs are the result of a wider combination of cytokines. 
That is the case of SAA that requires the synergitic effect of bacterial LPS and several 
cytokines (mainly IL-1, IL-6, and TNF, but also LIF, CNTF, oncostatin M, IL-11, and 
cardiotrophin-1) to be produced (Benigni et al., 1996). 
The main structural characteristics of APPs can be found in Table 1. Regarding their 
functions, summarized in Table 2, they are opsonisation and elimination of microorganisms 
and their products (CPR), activation of the complement system (complement C4a, C4b) and 
the lectin complement pathway (manan-binding lectin), inhibition of certain enzymes 
(alpha-1-antitrypsin, alpha-2-antiplasmin) or interleukins (interleukin-1 receptor antagonist 
protein), blockade of free radicals and/or elimination of haemoglobin residues 
(haptoglobin, serotransferrin, hemopexin), regulation of the immune response (serum 
amyloid P), coagulation and tissue repair/remodelling (fibrinogen, plasminogen), transport 
of ions (apolipoproteins, calcitonin precursor) and hormones (serum albumin), etc. Others, 
like alpha 2-macroglobulin and the coagulation factors, also play an important role in 
wound healing, because they collaborate with the immune system by increasing the 
vascular permeability, because they have chemotactic properties, or even because they are 
able of trapping pathogens in local blood clots. 
3. Acute phase proteins currently used in routine clinical practice 
As compared with cytokine and other short distance mediators of cellular responses 
production, which occurs in pulsed patterns cleared from the circulation within a few hours 
due to their small size, the native molecular mass of APPs secreted by the liver is larger than 
the kidney filtration cutoff (about 45 kDa). An example is albumin, which is just larger and 
has a lifetime of about 21 days. This fact, together with their large half-life, ensures an 
extended residence time in plasma, which means that levels of some APPs may remain 
unchanged for days and may be useful for diagnostic purposes. Currently, alterations in 
levels of some APPs are used to assess either the health/nutritional status of an individual 
or, mainly, to check for the presence of reactive processes, which has more advantages than 
measuring IL-6, a sensitive indicator of inflammation or infection but with a normal range of 
0-5 pg/ml and short plasma clearing times. An analysis of US Food and Drug 
Administration (FDA) approvals for IVD assays aimed to the quantitative detection of acute 
phase reactants reveals about 80 companies involved (Table 3), of which 15 dominate the 
market: Abbott Laboratories, Beckman Coulter, Dade Behring, Diasorin, Globalemed, 
Kamiya Biomedical, Kent Laboratories, Nitto Boseki, Olympus Life Science Research, Ortho-
Clinical Diagnostics, Polymedco, Randox Laboratories, Roche Diagnostics, Siemens Medical 
Solutions Diagnostics, and The Binding Site. 
About 51% of FDA-cleared or approved IVD assays are aimed to the detection of unique 
plasma or serum proteins that carry out their normal function in plasma. Most of these 
proteins are negative or positive acute phase reactants, like albumin, C-reactive protein,  1 
antitrypsin, transferrin, ceruloplasmin, or fibrinogen. Table 4 summarizes different tests 
from the companies listed in Table 3 intended to the detection of APPs in clinical practice. 
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Table 1. Main characteristics of APPs. There are represented the classical APPs and other 
proteins that have been reported as inflammation related proteins, and cited as putative 
APPs. Abbreviatures: Alternative Sequence, Alt-Seq; Disulfide Bond, -S-S-; 
Immunoglobulin, Ig; Interleukin, IL; Major Histocompatibility Complex, MHC; Modified 
residue, Mod-Res; Natural variants, Nat-Var; Phosphoserine, PSer; Phosphothreonine, PThr; 
Phosphotyrosine, PTyr; other abbreviatures are specified in the text. 
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Table 2. Main functions of Acute Phase Proteins. 
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Existing APPs test provide a spectrum of clinical information, including definitive diagnosis 
of acute events (e.g. CRP), prediction of disease risk (CRP increases in coronary disease) or 
detection of disease recurrence. Thus, if we check the clinical diagnostic catalog at the 
Beckman Coulter home page, one of the companies with the broader list of IVD tests for 
APPs (Table 3), we will find that those tests have the following intended uses 
https://www.beckmancoulter.com/eCatalog/Catalog/Disease_Management): albumin, to 
evaluate the hepatic/renal function, infectious diseases, inflammatory responses or 
nutritional assesment; alpha 1 acid glycoprotein, to assess the existence of infectious 
diseases or inflammation; alpha 1 antitrypsin, to check the presence of infectious diseases or 
inflammation; alpha 2 macroglobulin and antithrombin III, to detect anemia, thrombofilia or 
to assay the hepatic function; ApoA1 and ApoB, to measure the cardiovascular risk; 
ceruloplasmin, for the evaluation of the hepatic function or the detection of 
infection/inflammation; complement factors (C3 and C4), to evaluate the liver function or 
unmask autoimmune or inflammatory processes; fibrinogen, for thrombofilia and bledding 
disorders detection; haptoglobin, to uncover infectious diseases, inflammation, and 
anemia; plasminogen, to assess fibrinolysis; transferrin, to value the presence of anemia, 
the nutritional status, the presence of infectious diseases, or the renal function; and finally 
transthyretin/prealbumin, for hepatic function and nutritional assesment. In addition, 
detection of beta 2 microglobulin (e.g. Quantikine® IVD® Human 2M Immunoassay, 
R&D) is an aid in the diagnosis of autoimmune diseases (rheumatoid arthritis, systemic 
lupus erithematosus), viral infections or reduced glomerular filtration rates (kidney 
diseases). On the other hand, low levels of plasminogen activator inhibitor 1 (PAI-1) are 
linked to bleeding, while its elevation is related with an increased number of blood clots 
(surgery, infection, diabetes) and elevated risk of heart attack or coronary artery disease 
(CAD).  
 
 Company name   Company name  
1 Abaxis, Inc ABX 40 
Health Chem Diagnostics, 
Llc 
HCD 
2 Abbott Laboratories ABL 41 Horiba Abx HOR 
3 Access Bio, Inc ACC 42 
Human Diagnostics 
Worldwide 
HDW 
4 Affinity Biologicals, Inc AFF 43 Ibl, Gmbh IBL 
5 
Alfa Wassermann 
Diagnostic Technologies, 
Inc 
AWDT 44 Immunostics, Inc IMMTICS 
6 American Diagnostica, Inc AMER 45 Immuno, Gmbh IMM 
7 Amico Lab, Inc AMI 46 
Instrumentation Laboratory, 
Co 
ILAB 
8 Arkray, Inc ARK 47 
Jas Diagnostics Systems, 
Gmbh 
JAS 
9 Arlington Scientific, Inc ARL 48 Kamiya Biomedical, Co KB 
10 
Axes-Shield Diagnostics, 
Ltd 
AS 49 Kent Laboratories, Inc KL 
11 Bacton Assay Systems BAS 50 Medical Diagnostic MDT 
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Technologies 
12 Baxter Diagnostics, Inc BAX 51 
Medical Laboratory 
Automation Systems, Inc
MLAS 
13 Beckman Coulter, Inc BC 52 
Nitto Boseki Co., Ltd 
(Medical Division)
NB 
14 Biocheck, Inc BCK 53 Novamed, Ltd NVM 
15 Bio/Data, Corp BIODT 54 
Olympus Life Science 
Research Europa, Gmbh 
(Europa)
OLSR 
16 Biokit, S.A. BK 55 
Ortho-Clinical Diagnostics, 
Inc
OCD 
17 Bio-Medical Products, Corp BMP 56 Polymedco, Inc POL 
18 Biopool AB BAB 57 Precisa Intl Corp PREC 
19 Boditech Dioagnostics, Inc BODIT 58 Quidel Corp QUID 
20 Brahms AG BAG 59 R2 Diagnostics, Inc R2 
21 
Carolina Liquid 
Chemistries, Corp
CLC 60 Randox Laboratories, Ltd RDXL 
22 Cenogenetics, Corp CNG 61 Reagents Applications, Inc RA 
23 Cezanne SAS CSAS 62 Remel, Inc REM 
24 Cliniqa, Corp CLINQ 63 R&D Systems R&D 
25 
Covance Research 
Products, Inc
CRP 64 Roche Diagnostics, Gmbh ROD 
26 Dade Behring, Inc DB 65 
Rowley Biochemical 
Institute, Inc
ROW 
27 Dako Denmark A/S DAK 66 Seradyn, Inc SER 
28 Dexall Biomedical Labs, Inc DEX 67 
Shanghai Shenfeng 
Biochemistry Reagent Co, 
Ltd
SSBR 
29 Diagnostica-Stago DS 68 
Siemens Medical Solutions 
Diagnostics
SMSD 
30 Diagnostix Technology, Inc DT 69 Stago R&D STG 
31 Diamedix Corp DIAMED 70 Sterling Diagnostics, Inc SD 
32 Diasorin, Inc DIA 71 Teco Diagnostics TECO 
33 
Diasys Diagnostics 
Systems, Gmbh
DSYS 72 Texas Immunology TEXAS 
34 Dominion Biologicals, Ltd DOM 73 The Binding Site, Inc TBS 
35 DRG Instruments, Gmbh DRGI 74 Tosoh Bioscience, Inc TOS 
36 Eucardio Laboratory, Inc EUL 75 Trinity Biotech, Plc TB 
37 Fisher Diagnostics FISH 76 
Ventana Medical Systems, 
Inc
VMS 
38 Genetic Technologies, Inc GEN 77 Wako Pure Chemicals, Inc WAKO 
39 Globalemed, Llc GBL 78 
YK & E Advance Trading, 
Inc
YK&EAT 
Table 3. Some companies developing in vitro diagnostics (IVD) tests for clinical use. 
This table is not expected to be a comprehensive summary of all existing IVD companies. 
Mainly, data have been collected from different sources, like the US Food and Drug 
Administration Home Page (http://www.fda.gov), ZapConnect.com, or the home page of 
each company.  
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Amongst this first group of IVD tests for APPs, C-reactive protein/CRP is, by far, the most 
frequent offered by different companies (Table 4). That is due to a dual use: On the one 
hand, a low sensitivity test for inflammation or infectious/autoimmune diseases. On the 
other hand, systemic inflammation and CRP levels increase as the amount of visceral 
adipose tissue and the waist circumference become excessive, and that is because CRP (as 
well as the fibrinolysis inhibitor PAI-1) are not only produced by liver but also by 
adipocytes (Libby et al., 2010). Based on that, a high-sensitivity assay for cardiovascular risk 
(denoted hs-CRP) has been developed to predict future clinical cardiovascular events. 
Elevation of average hs-CRP level is linked to atheroesclerosis, and therefore point to a 
higher potential of stroke, myocardial infarction or severe peripheral vascular disease 
development. Thus, apparently healthy people with some inflammation (above median 
hsCRP) but below median levels of low-density lipoprotein (LDL) could nonetheless benefit 
from statin therapy (Libby et al., 2010). 
Moreover, these companies are continuosly adding new products to their growing portfolio 
of IVD assays, as it is the case for some acute phase reactants (Table 4). For example, tests for 
factor VIII (hemophilia A) and von Willebrand (von Willebrand disease) are included within 
the pannels of reagents to check hemostasis, and alpha 1 microglobulin is been introduced 
in market for the functional evaluation of liver and kidney, diabetes and stroke. As well, 
elevation of calcitonin  precursor levels in plasma represent a high risk for progression to 
severe sepsis if the measurement of this acute phase reactant is done shortly after the 
systemic infection process has started (on the first day). Still, there are other IVD tests that 
have not been included in Table 4, like properdin Factor B (autoimmune diseases) or 
apolipoprotein (a)(cardiovascular risk), that are also manufactured by some companies.   
A large majority of APPs are typically measured by enzyme immunoassays (EIA, ELISA), 
but also by immunoturbidimetric or nephelometric technologies through chemistry 
analyzers such as Alfa Wassermann Alera/ACE, Roche/Hitachi, Roche/Cobas, Beckman 
Synchron®, Beckman/Olympus, Abbot Aeroset, Siemens/Bayer Advia or Siemens/Dade 
Dimension. There are some radioimmuno- (RIA) (e.g., Abbott Beta-2-Microglobulin RIA) 
and chromogenic assays too (e.g., BCG method for albumin), and some of these analytes 
have waived versions (simple and accurate, according to the CLIA complexity classification; 
e.g., Abaxis, Inc). 
4. New methods and technologies for the quantification of acute phase 
proteins: APPs as disease biomarkers 
The high-throughput genomic and proteomic technologies, combined with bioinformatics, 
give the most recent approaches to the study and analysis of APPs in human body fluids 
(plasma, serum). There are different methods that permit the simultaneous 
qualitative/quantitative analysis of several APPs from small volume of samples: 2-DE/MS, 
2-DE-DIGE/MS, MALDI-TOF-MS, SELDI-TOF-MS, label-free LC-MS profiling, CE-ESI-MS, 
isotope tagging/MS/MS, or antibody arrays for serum profiling. Proteomic methods can 
now detect more than 1000 proteins in plasma at the same time. However, the 
comprehensive analysis of the proteome of any body fluid is still beyond our reach, despite 
great methodological advances in recent years. Several major challenges must be faced by 
researchers. For instance, proteomics of body fluids is limited to a ~g/L (ng/mL)  
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ABX X                         
ABL X X X     X X X X  X   X      X X   
ACC             X             
AFF              X            
AMI           X               
AWDT X       X              X    
AMER                  X        
ARK X                         
ARL             X             
AS         X                 
BAS        X                  
BAX                  X        
BC X X X  X X X X X X X  X   X   X   X X   
BCK         X    X             
BIODT               X           
BK  X X      X    X           X  
BMP             X             
BAB                  X        
BODIT             X             
BAG            X              
CLC X          X     X      X    
CNG             X             
CSAS            X              
CLINQ                X       X   
CRP   X                       
DB X X X X  X X X X X X  X X  X X  X  X X X   
DAK         X                 
DEX             X             
DS   X X  X X    X    X    X X      
DT             X             
DIA  X X   X X  X X X  X   X   X   X X   
DIAMED           X               
DSYS        X               X   
DOM             X             
DRGI        X                  
EUL        X                  
FIS               X           
GEN             X             
GBL   X   X  X X  X  X      X  X X    
HCD   X                       
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HOR                       X   
HDW X       X   X  X  X       X    
IBL           X               
IMMTICS             X             
IMM        X                  
ILAB              X X           
JAS                       X   
KB  X X  X  X X   X  X X X X   X   X X   
KL  X X   X    X X  X   X X     X X   
MDT                  X        
MLAS                  X        
NB  X X    X    X     X   X   X X   
NVM        X                  
OLSR  X X     X X X X  X   X      X    
OCD   X     X   X  X   X      X X   
POL X       X   X  X         X X   
PREC             X             
QUID           X               
R2                          
RDXL X       X   X  X         X X   
RA  X         X  X   X          
REM             X             
R&D         X                 
ROD   X      X  X  X   X      X X   
ROW               X           
SER             X             
SSBR        X               X   
SMSD X  X   X  X X  X X X         X    
STG           X        X       
SD             X             
TECO             X             
TEXAS             X             
TBS  X X   X X  X X X     X   X  X X X   
TB       X        X    X X      
TOS         X                 
VMS   X                       
WAKO        X     X          X   
YK&EAT        X                  
Table 4. In vitro diagnostic (IVD) tests for the quantitative determination of acute phase 
proteins in serum or plasma. 
This table is not intended to be a comprehensive summary. Data come from different 
sources, like the US Food and Drug Administration Home Page (http://www.fda.gov), 
ZapConnect.com, or the home page of each company. Sometimes this one does not offer 
directly IVD tests for some APPs, but can do it through strategic alliances that are not 
reflected in Table 3 (e.g., Beckman Coulter and Instrumentation Laboratory and the 
HemosIL® Fibrinogen-C kit). Abbreviations used for the name of the companies are the 
same as in Table 3. Abbreviations for APPs are the same as in Table 1.  
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sensitivity, which is roughly 1000-fold less sensitive than the most specific immunoassays. 
Another additional problem is the range of protein concentrations in body fluids. The 
dynamic range of plasma proteins concentrations spams from that much as 40 mg/mL for 
albumin (50% of the total mass of plasma proteins) to less than 4 pg/mL; i.e., the 
concentration of many cytokines. Therefore, we are talking about 10-12 orders of magnitude, 
which means that disease-mediated alterations in soluble mediators (e.g., cytokines), or 
modifications in those released into the circulation through cell-leaking processes during 
normal cell turnover (apoptosis) or specific injuries (e.g., myocardial infarction), are hardly 
detectable. For example, the most common technology for fractionating and identifying 
proteins, 2-DE, has a range of detection of no more than 3-4 orders of magnitude with 
differential gel electrophoresis (DIGE). About 99% of total protein mass in plasma depends 
on only 22 abundant species, like albumin (35-45 mg/mL), IgG, IgA, IgM (12-18 mg/mL), 2 
and -lipoproteins (LDL; 4-7 mg/mL), fibrinogen (2-6 mg/mL), 1-antitrypsin (2-5 
mg/mL), 2-macroglobulin (2-4 mg/mL), transferrin (2-3 mg/mL), 1-acid-glycoprotein (1 
mg/mL), hemopexin (1 mg/mL), -lipoproteins (HDL, 0.6-1.5 mg/mL), haptoglobin (0.3-2 
mg/mL), prealbumin (0.3-0.4 mg/mL) or ceruloplasmin (0.3 mg/ml). Most of them are 
acute phase reactants; i.e., plasma resident proteins with a molecular mass larger than the 
kidney filtration cutoff and large half-lives, both characteristics ensuring an extended 
residence time and high protein concentrations (45 mg/mL-0.001 mg/mL). Thus, this high 
abundance makes them easily accessible to proteomic technologies, although there are still a 
couple of questions to consider: complexity of this family of proteins and their time-
dependent concentration modulation (kinetics). 
Regarding complexity, the most important APPs are usually glycoproteins. This means that 
APPs, like immunoglobulins, are highly heterogeneous (Anderson and Anderson, 2002). 
The difficulty of their analysis is even enhanced by processing events, that lead to the 
generation of smaller proteins or peptides from larger precursors (both the plasma and cells 
contains numerous proteases), or the presence of genetic variants in acute phase reactants as 
apoE, apoH, transferrin or haptoglobin. Two-dimensional electrophoresis (2-DE) was the 
first used method in clinical biofluids proteomics, and still is one of the most used nowadays 
for different reasons. After the introduction of high resolution 2-DE in 1975 this technique 
was applied to the plasma proteins (Anderson & Anderson, 1977). These authors were able 
to resolve by 2-DE about 300 or more spots and a number of about 40 distinct plasma 
proteins. This initial amount has been extended to 626 identified spots, 1966 detected spots 
and 69 proteins in the current Swiss 2D-Page Web site (http://expasy.org/swiss-2dpage), 
which may represent the limit in terms of 2-DE analysis of unfractionated plasma. 
Therefore, it was clear very soon than 2-DE had limitations with respect to the resolution to 
cope with the extraordinary dynamic range of plasma proteins concentrations and the 
complexity issue, apart from additional problems: low and high molecular weight, 
hydrophobic, and very acid or basic proteins. Still, isolectric points of APPs are mostly 
between pH 5 and 6, and these proteins are originated mainly from liver secretion (not cell 
leakage; i.e., hydrophilic) and have a medium-high molecular size. In addition, there are 
means to reduce sample complexity and enhance the loading capacity of 2-DE (see below). 
Therefore, 2-DE is a technique specially suited to screen the acute phase response, and can 
be even essential to determine the post-translational and genetic modifications of APPs.  
Nevertheless, and largely because of novel methods of serum fractionation and MS based 
protein identification, after the turn of the century the number of plasma proteins that could 
be identified increased over time. Thus, thanks to extensive fractionation serum 
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fractionation and tandem mass spectrometry, Adkins et al. (2002) were able to identify 490 
proteins. That number suffered a huge increase in 2004, to achieve an identification of 1,175 
non-redundant plasma proteins, by using multidimensional chromatography and MS 
analysis (Anderson et al. 2004). At present, the Human Proteome Organization (HUPO) 
Plasma Proteome Project (PPP) has a list of 3020 plasma proteins (http://www.hupo.org/ 
research/hppp/) 
4.1 Quantitative proteomics technologies applied to the study of APPs 
However, the elaboration of a detailed list of serum/plasma proteins provides relatively 
limited biological information. To understand the biology of any pathological process, 
quantitative analysis of these proteins is essential. Perhaps, 2-DE or 2-DE fluorescence 
differential gel electrophoresis (DIGE), followed by MS analysis, remains as the most 
commonly used method (see Table 5). DIGE is a quantitative technique that enhance the 
dynamic range of 2-DE up to four orders of magnitude. DIGE is commercially available 
from GE Healthcare, and allows the direct comparison of different samples at the same time 
on a single 2-DE gel. This technique involves the use of up to three different samples and 
three cyanide dyes (Cy2, Cy3, and Cy5). These dyes have an NHS-ester reactive group 
designed to covalently attach to the epsilon amino group of lysine of proteins via an amide 
linkage. In addition, dyes label 1-2% of all the available proteins (minimal labelling, about 
one dye molecule per protein), without changing their pI and adding only 0.5 kDa to the 
protein mass. Normally, a pooled sample, comprising equal amounts of each of the initial 
samples within the study, is labelled with Cy2 and used as internal control. This internal 
standard allows normalization and is an effective way to increase accuracy and 
reproducibility during quantification. On the contrary, one particular disadvantage of DIGE 
is the equipment required for visualization and spot excision, and another major problem 
with these 2-DE based methodologies is that they are labor intensive and difficult to 
automate. In addition, as we have just commented, they are not able to effectively mine the 
low abundance biofluids proteome (<100 ng/ml). Therefore, the detected proteins limit 
primarily to high (0.1–40 mg/ml) and medium abundance (0.1–100 g/ml) species, which is 
enough to study the classical acute phase reactants (e.g., CRP <10 g/ml), but does not 
allow to find new ones. All these limitations of 2-DE based methods are driving the 
development of new proteomic methodologies for serum/plasma profiling that seek to 
reduce the workload of 2-DE (since they use automated equipment), such as MALDI-TOF-
MS, SELDI-TOF-MS, label-free LC-MS profiling, CE-ESI-MS, isotope tagging/MS/MS, or 
antibody arrays. Although it is outside the scope of this chapter to review comprehensively 
these techniques, we will go through a brief summary of some of them. 
Simple adsorption/washing/desorption methods are fast, easily automated and have a 
widespread use (Table 5). In matrix-assisted laser desorption/ionization mass spectrometry 
(MALDI-TOF-MS) samples are digested with trypsin and deposited on the MALDI plate 
prior peptide mass fingerprinting (PMF) or partial sequencing of peptides (MS/MS; e.g., 
MALDI-TOF/TOF). In surface-enhanced laser desorption/ionization (SELDI) (e.g., 
ProteinChip®, Ciphergen Biosystems, Palo Alto, CA) different chromatographic surfaces 
(hydrophobic, hydrophilic, etc) are used on a metal array to bind a subset of proteins from a 
sample. The unbound proteins are washed away, the bound proteins are overlaid with an 
organic matrix, and finally this fraction is profiled by MS analysis (e.g., MALDI-TOF-MS), 
generating rather simple mass spectra which can be easily analyzed. SELDI is a very useful 
method for high throughput screening, although this approach is not very reproducible and 
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quite cumbersome to identify detected proteins, since require mass spectrometers such as 
FT-ICR-MS instruments to get a direct fragmentation of high molecular weight ions.  
However, patterns of peaks are usually found to be useful for the classification of 
pathological samples (Table 5).   
Combination of online sample preparation with liquid chromatography (LC) and mass 
spectrometry (MS; LC-MS) is a common practice. Leaving aside the peptidomics approach, 
which is perhaps less interesting to study acute phase reactants, these medium-high 
molecular weight proteins can be analyzed through shotgun proteomics (Murakoshi et al., 
2011). During the shotgun proteomics approach the entire serum/plasma proteome is 
submitted to trypsin digestion followed by peptides separation through one or normally 
(due to the very complex mixture of peptides) several liquid chromatography steps prior to 
MS. Multidimensional protein identification technology (MudPIT), for example, consists of a 
2D chromatography separation prior to electrospray (ESI)-MS. In MudPIT the first 
dimension is normally a high loading capacity strong cation exchange (SCX) column, while 
the second dimension is reverse phase chromatography. After this extensive peptide 
fractionation and MS, the fragmentation data are matched against sequence databases using 
different software (e.g., SEQUEST) in order to identify serum/plasma proteins. However, 
several runs are required to get a comprehensive analysis of the whole proteome and, as 
with 2-DE, there are problems to mine the low abundant subproteome. In addition, 
qualitative over quantitative data are obtained by LC-MS, although the use of label-free LC-
MS profiling (Wesner et al., 2010) or techniques such as isotope-coded affinity tag (ICAT) 
(Lin et al., 2009), isobaric (iTRAQ) and MRM (multiple reaction monitoring; mTRAQ) tags 
for relative and absolute quantitation (Boylan et al., 2010; Kanq et al., 2010), or 18O labelling 
(Qian et al., 2010) allows for quantitative comparisons between different samples. Finally, 
there are other high throughput methods to analyze the acute phase response in 
serum/plasma samples, such as capillary electrophoresis connected to electrospray 
ionization MS (CE-ESI-MS) or antibody arrays. Regarding antibody arrays, their main 
problem is that these methodologies are not discovery based; i.e., the only proteins that can 
be detected and quantitated are those targeted by the available antibodies. Moreover, 
several technological advances must be accomplished before truly high density antibody 
microarrays are readily available (Borrebaeck & Wingren, 2009)     
4.2 Complexity and sensitivity: Strategies to enhance the detection of lower abundant 
APPs 
The unmasking of low abundant proteins (protein depletion), together with new 
technologies with enhanced resolving power, will provide access to more sensitive and 
specific biomarkers, and it is likely that some of them will represent new acute phase 
reactants. One way to reduce sample complexity and enhance the capacity to detect proteins 
or peptides at lower concentrations is to remove high-abundance proteins selectively. Only 
albumin (3.4-5.4 g/L) and immunoglobulins (IgG, 7.2–15 g/L; IgA, 0.9–0.33 g/L; IgM, 0.5–
2.5 g/L; IgD, 0–0.4 g/L; IgE, 100–200 g/L) account for >70% of total serum proteins. 
Several affinity columns, based on dye ligands (e.g., Cibacron-blue) or specific antibodies 
(e.g., IgY, IgG), have been developed for albumin removal, while either thiophilic gels 
(Salgado, 2010) or resins with fixed antibodies (anti-IgG and, sometimes, even anti-IgA or 
anti-IgM) or immunoglobulin binding-proteins (protein A, protein G, protein A/G mixtures, 
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protein L) have been used for immunoglobulins substraction methods (Fang & Zhang, 
2008).  
Although albumin is an acute phase reactant, removal of this abundant protein together 
with immunoglobulins facilitate the detection of less abundant or previously masked new 
acute phase reactants. A good example of this comes from our 2-DE analyses of human 
serum samples, where we were able to identify both leucine rich 2 glycoprotein (LRG) and 
apolipoprotein H (ApoH) (Salgado, 2010). LRG is a positive acute phase reactant whose 
concentration in serum (LRG; ~ 3 g/ml) is close to the detection limit of 2-DE 
electrophoresis (g/mL range), and therefore very difficult to show in order to measure 
quantitative differences. The second one, apolipoprotein H, has a position coincident with 
immunoglobulin G heavy chains in 2-DE maps, appearing fully hidden prior 
albumin/immunoglobulins depletion (Salgado et al., 2010).   
Sometimes, methods to eliminate albumin or immunoglobulins can be rather inespecific. For 
example, dye-ligand affinity columns (e.g, Cibracron Blue-based kits), still used in 
proteomic studies due to its relatively low cost, show a low specific binding for albumin and 
causes retention of unwanted proteins (Bellei et al., 2011). Thus, to achieve deeper and more 
specific protein depletion, different companies have developed several alternatives, like 
antibody immunoaffinity media or combinatorial peptide libraries. An example is the 
MARS-Hu-14 column (Agilent Technologies, Santa Clara, California, USA), intended to 
deplete the 14 most abundant proteins from serum or plasma samples. Another one is the 
ProteoPrep® 20 Plasma Immunodepletion spin or LC-column from Sigma (St Louis, MO, 
USA), allowing the simultaneous depletion of 20 abundant proteins (97-98% of 
plasma/serum proteins) and up to 50-fold increased protein loads (according to the 
company data). However, despite these clear benefits, the use of these affinity 
chromatography technologies generates great losses of information about the acute phase 
response, since all the removed proteins are acute phase reactants themselves. For example, 
the ProteoPrep® 20 Plasma Immunodepletion column from Sigma eliminates albumin, IgG, 
transferrin, fibrinogen, IgA, ┙2- Macroglobulin, IgM, ┙1- Antitrypsin, complement C3, 
haptoglobin, apolipoprotein A1, A3 and B; ┙1-Acid Glycoprotein, ceruloplasmin, 
complement C4, C1q, IgD, transthyretin, and plasminogen.  
Another choice to reduce sample complexity in order to study the acute phase response is to 
use ProteoMiner (Bio-Rad Laboratories) or ProSpectrum Libraries (Prolias). Both are 
approaches based upon a combinatorial peptide libraries displayed on beads. These beads 
are incubated with the starting material and are capable of interacting with most of proteins 
in serum/plasma proteome. Because the binding capacity of those beads is limited, and each 
peptide combination binds, in theory, to a unique protein sequence, the high-abundance 
proteins (e.g., albumin, immunoglobulins) quickly saturate the beads, so their excess can be 
washed away. Thus, low-abundance proteins are concentrated in the final sample, thereby 
decreasing the dynamic range of proteins and becoming a good alternative to 
immunoaffinity separation media. Using this technology, modification in APPs like 
apolipoprotein A1, apolipoprotein A4, antithrombin-III, C4a complement, vitamin D 
binding protein or apolipoprotein J can be easily traced (our unpublished data; Kolla et al., 
2010).  
Prefractionation is another choice to augment the depth of the analysis, even though at the 
expense of having to analyze multiple subsamples. One example is to select narrower pH 
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ranges during the first dimension in 2-DE, to visualize only the part of the serum/plasma 
proteome we are interested in. Another way, perhaps not so popular, is to use preparative 
in-solution isoelectric focusing (e.g., Zoom IEF fractionator ®, Invitrogen) as the first step in 
body fluid analysis prior to 2-DE or, preferably, an automated method (e.g., LC-MS). 
Finally, the last strategy that we will mention to reduce sample complexity and cover more 
of the lower-abundance acute phase proteome is to enrich some protein families specifically. 
Thus, most of acute phase reactants are glycoproteins. Therefore, they can be enriched by a 
number of different techniques; one of the most commonly used is lectin affinity 
chromatography. More than 100 different lectins (concanavalin A, wheat germ agglutinin, 
peanut agglutinin, etc) are commercially available, which differ in specificity (a drawback of 
lectin chromatography). Glycoproteins are involved in many diseases (e.g., cancer), so the 
study of the O- and N-linked glycosilated APPs may therefore be particularly interesting 
(see below).    
There is still another concern to address, which is associated with the removal of proteins 
like serum albumin or immunoglobulins. These high abundant proteins appear to fullfill the 
function of carriers for less abundant species, especially low molecular weight proteins 
(cytokines, growth factors, etc) that can only escape kidney clearance when bound to these 
high molecular weight carrier proteins. Moreover, some APPs, which are not so small, are 
also bound to these carrier proteins. Therefore, immunoaffinity subtraction may potentially 
remove non-targeted and potentially important APPs from serum/plasma samples, which 
may lead to unnoticed loses of information. In other words: what do we know about the 
interactome of APPs? For instance, it is known that transthyrretin binds another APP, the 
retinol binding protein (Folli et al., 2010), and the same happens with albumin (Gundry et 
al., 2007). In fact, almost every single APP has been described associated with albumin, like 
retinol-binding protein, 2-antiplasmin, complement factors, fibrinogen ( chain), histidine-
rich glycoprotein, prothrombin, serum amyloid A4, 1-acid glycoproteins 1 and 2, 1-
antichymotrypsin, 1-antitrypsin, 1B-glycoprotein, 2HS-glycoprotein, antithrombin III, 
apolipoproteins, ceruloplasmin, haptoglobin, hemopexin, inter-a-trypsin inhibitor (heavy 
chain H4), leucine-rich 2 glycoprotein, paraoxonase 1, plasminogen, transferrin, 
transthyretin, vitamin D-binding protein or zinc-2-glycoprotein (Gundry et al., 2007; 
Salgado et al., 2010). Immunoglobulins are another example, since they fix complement 
factors. Immunoglobulins-complement factors interactions may cause unwanted loss of the 
second ones during the process of removing antibodies from biological fluids, which could 
account for the reduced levels of complement factors (C1, C3, C4) found in some clinic 
proteomic studies (Table 5). Finally, another good example comes from the association of 
haemoglobin and its scavenger protein haptoglobin with ApoA1 under an inflammatory 
context (Salvatore et al., 2007; Watanabe et al., 2009), so removal of haptoglobin can affect to 
ApoA1 detected levels, and vice versa. Despite these different setbacks, it can be stated that 
immunoaffinity depletion of just the two most abundant plasma proteins (i.e., albumin and 
immunoglobulins) still appears to be necessary, or at least beneficial, to enhance the 
resolving power (e.g., in 2-DE), reduce technical variation, detect or unmask lower abundant 
acute phase reactants (e.g, ceruloplasmin, C1q, ceruloplasmin, LRG) or reveal qualitative or 
quantitative differences in this group of plasma proteins more accurately. In any case, we 
always recommend analyze the retained fractions in order to extract more information from 
our clinical plasma/serum proteomic studies (Salgado et al., 2010).   
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Another problem of studying the APP is their modulation across the time. As commented in 
the introduction, the so-called negative acute phase reactants are highly abundant proteins 
which are rapidly down-regulated in response to a variety of stimuli, (e.g., transthyretin). 
The same “stressors”, in turn, cause the up-regulation of another important subclass: the 
positive APPs. This last class may be divided into three subclasses (I-III), based on their 
normal plasma concentrations. Class I, like ceruloplasmin (0.3 mg/mL) or complement 
factors C3 (0.8-1.7 mg/mL) or C4 (0.15-0.65 mg/mL), whose concentration may increase by 
50%; Class II (1-acid glycoprotein, ~1 mg/mL; 1-antitrypsin, 2-5 mg/mL; 1-
antichymotrypsin, 0.3-1.6 mg/mL; haptoglobin, 0.3-0.2 mg/mL; fibrinogen, 2-6 mg/mL) 
begin to increase 24 to 48 hours and reach to their maximum level (two to five fold 
enhancement) in about 7-10 days, and require about two weeks to return to their normal 
levels; and finally class III (e.g, C reactive protein/CRP < 5 g/mL; serum amyloid A/SAA; 
< 10 g/mL), whose concentrations rise as early as 4 hours after inflammatory stimulus and 
attain their maximum levels within 24 to 72 hours (concentration may increase up to 1000 
fold) and also decline very rapidly. Thus, depending on the acute/chronic nature of the 
pathology or the sampling time, one may get different results.            
4.3 Clinical proteomics 
The field of clinical proteomics holds tremendous potential for discovery of noninvasive 
diagnostic and prognostic biomarkers or the identification of novel drugs targets, although 
there is a lack of approved IVD biomarkers (Table 4) based on clinical proteomics data 
(Anderson, 2010). However, scientists have accumulated during the last years a huge 
amount of high-throughput proteomic data with a true translational potential. Table 5 
summarizes a literature review on different proteomics strategies used for the study of 
serum/plasma samples from several important diseases, as well as an overview on the 
major APPs alterations observed.  
There are at least three sources of plasma/serum biomarkers: a) the primary diseased 
tissue, such as endothelial cells in atherosclerosis or neoplastic cells in cancer; b) the 
microenvironment around the primary cells; c) the systemic response to these local 
alterations, where APPs are involved. APPs are altered in bacterial infections, fractures, 
tumors, Crohn´s disease, surgery, rheumatoid arthritis,burns or systemic vasculitis; 
however, they remain unaltered in others. The use of this third source of biomarkers has a 
clear advantage, as the APR is a kind of “amplificated biological response” (Omenn et al., 
2007). Maybe for that reason, most of candidate biomarkers discovered in clinical 
proteomic studies using biofluids (plasma, serum, urine, cerebrospinal fluid, pleural 
effusion, etc) are APPs, which are shared among different pathological situations, like 
different cancers or autoimmune diseases. Therefore, contrary to single proteins 
biomarkers like PSA (prostate cancer), CA 125 (ovarian cancer), CEA (pancreatic cancer or 
CA 19-9 (breast cancer), which show a low sensitivity and specificity during disease 
detection, acute phase reactants (for example, C-reactive protein and cardiovascular risk 
detection) are more sensitive, but lack specificity. For example, Table 5 shows that CRP is 
elevated in allogeneic hematopoietic stem cell transplantation/HSCT, Down syndrome 
(maternal plasma), or hepatocellular carcinoma. Similarly, alpha 1 acid glycoprotein, 
alpha 1-antichymotrypsin, 1- B-Glycoprotein, antithrombin  III, apoA1, ceruloplasmin, 
leucine rich glycoprotein, prothrombin, serum amyloid A, serum amyloid P component, 
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transferrin, transthyretin, vitamin D Binding Protein or zinc 2-glycoprotein are 
systematically either down- or up-regulated in different diseases (low specificity) (Table 
5).  This fact does not mean they are not useful as biomarkers. Rheumatoid arthritis (RA) 
is an autoimmune disease affecting 0.5-1% of adults characterized by persistent synovitis, 
systemic chronic inflammation and presence of autoantibodies. About 50-80% of RA 
patients are seropositive for rheumatoid factor (RF; IgM and IgA autoantibodies directed 
against the Fc region of IgG), antibodies against cyclic citrullinated peptides (anti-CCP), 
or both. Anti-CCP antibodies are more sensitive and specific for RA diagnosis than RF, 
which is present in up to 20% of elderly individuals, and also seem to be a better predictor 
of progressive joint destruction (Scott et al., 2010). Early diagnosis of RA is fundamental to 
achieve significantly better clinical outcomes, and acute-phase reactants can help to assess 
tha probability of developing RA once there are evidences of inflammatory arthritis. 
Indeed, the low specific C-reactive protein is part of the ACR (American College of 
Rheumatology)/EULAR (European League Against Rheumatism) 2010 criteria to classify 
both early and established disease. Also on this regard, in 2010 our group published a 
preliminary 2-DE study using Immunoglobulins/HSA-depleted serum samples from 
healthy individuals and recently diagnosed/untreated rheumatoid arthritis (RA) patients. 
This work found that leucine rich glycoprotein was significantly upregulated, while 
antithombin III was downmodulated (Salgado et al., 2010). Separately, Satoshi Serada 
(Serada et al., 2010), using iTRAQ, found that leucine rich glycoprotein is increased in RA 
patients before therapy. Like C-reactive protein, leucine rich glycoprotein is a low specific 
biomarker, as elevations of this APP are observed in bacterial (toxic shock syndrome) and 
viral (HIV) infections, autoimmune diseases (Crohn´s disease, Behcet´s disease) and some 
kind of cancers. However, this novel biomarker may be particularly useful to monitor 
disease activity in patients with active disease but normal C-reactive protein levels 
(Serada et al., 2010). In clear contrast (Table 5), other APPs, such as alpha 1 antitrypsin, 
hemopexin and, curiously, haptoglobin (considered a positive acute phase reactant), show 
a higher variability. Perhaps, such variability is rather due to genetic or posttranslational 
based changes more than simple augmented or reduced levels (see below), but there is not 
doubt that this kind of APPs may be more specific and therefore attractive from a 
diagnostic point of view.  
Anyhow, the simple test paradigm, where one expects changes in the concentration of 
unique biomarkers linked to the diagnosis of single diseases, is gradually moving on to 
the use of multivariate tests. In classical clinical chemistry, a biomarker determination has 
diagnostic value only if compared with a reference interval including 95% (about 2 
standard deviations above and below the mean value) of the reference values from the 
reference population (normally “healthy” people, but not always). Thus, plasma levels of 
a particular disease biomarker should lie within that reference interval, and values 
outside that reference range could point out (in theory) a pathological situation. However, 
this is not so straightforward. As mentioned above, it seems not likely to find a fully 
specific acute phase protein, since other diseases may alter the blood levels of this 
biomarker too (Table 5). What is more, acute phase protein concentrations within non-
diseased subjects may vary substantially and overlap with those within diseased 
populations because: (A) genetic influences, like gender or race; (B) non genetic 
influences, like age, exercise, circadiam rhythm, season, smoking, diet or sleep; (C) 
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medical treatment, such as drug therapy; and (D) pre-analytical phase variation, including 
sample drawing (body posture, time of venous occlusion by the tourniquet), transport 
and preparation. Indeed, there is a strong evidence of genetic control of plasma protein 
abundance: ~ 12-95% of the quantitative variation in specific plasma protein levels is 
genetic in origin (Anderson & Anderson, 2002). Therefore, it is important to control both 
the analytical and biological variation in any clinical proteomic study of the acute phase 
response in order to predict the number of samples and replicates that should be analyzed 
to find statistically significant differences (Hunt et al., 2005). 
As we have just mentioned, most biomarker studies in scientific literature detecting acute 
phase response proteins are based on transversal/cross-sectional comparisons (e.g., healthy 
vs diseased group; Table 5). This approach suffers sometimes from large biological variation 
in the baseline values of APPs within the reference population, which, summed to the 
technical variation, generate a significant overlap with the concentration range of diseased 
populations. This overlap may mask the existence of significant changes and leads to low 
sensitivity (false negatives) and, especially for APPs, low specificity (false positives), once a 
cut-off value is set. ROC curves can help us to select such a discriminative value in order to 
maximize the specificity without renouncing to a good sensitivity level. Nonetheless, even if 
we find a sensitive and specific acute phase protein for a disease, the positive predictive 
value of that biomarker would depend, in the end, on the disease’s prevalence, since even 
specificities as high as 99% will result in false positive results of low prevalent pathologies 
(Hoffman et al., 2007).  
To solve these problems, two changes may help. The first one is the use of individual 
instead of population-based reference intervals for APPs (personalized medicine). 
Different authors have monitored the protein expression dynamics that take place within 
one individual to overcome all these limitations and to get more meaningful data; for 
example, to reveal serum/plasma biomarkers or to predict the recovery or treatment 
response during acute events such as trauma, infection or drug intervention. An example 
is the study of Han Roelofsen in 2007, who studied the kinetic of serum proteome before 
and after colon laparoscopic surgery (Roelofsen et al., 2007). Using SELDI-TOF-MS, this 
group could distinguish up to four groups of proteins based on their expression pattern 
kinetics. Thus, they identified serum amyloid protein and C-reactive protein as part of 
the positive slow response cluster, and transthyrretin as a negative reactant belonging to 
the fast response group. These authors were also able to observe serum amyloid protein 
differences between patients, related to their recovery from surgery (Roelofsen et al., 
2007). Another interesting work was the recent study on the serum proteome changes 
produced during allo hematopoietic stem cell transplantation by Joohyun Ryu (Ryu et 
al., 2010). The aim of this work was to find biomarkers suited for the diagnosis and 
follow-up of patients who experience complications after allo-HSCT (Table 5). Using 2-
DE analysis of HSA/IgG depleted sera obtained at different times (pretransplant, 7, 14 
and 21 days), these authors found 14 differentially expressed APPs. They observed three 
different expression patterns: A) serum amyloid P, ApoE and C-reactive protein, 
elevated 14 or 21 days post-HSCT; B) haptoglobin, alpha 2 HS glycoprotein, decreased 
upon HSCT; C) and APPs with irregular patterns. Based on their data, this group has 
suggested CRP as a risk factor for the development of major transplant-related 
complications, and haptoglobin as a prognostic biomarker of relapses in underlying 
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hematologic disease (Ryu et al., 2010). On the other hand, the second change consist in 
using multiplex panels of specific APPs (a proteome signature), which may improve 
diagnostic performance through the use of protein ratios (Gruys et al., 2006) or more 
sophisticated interpretive algorithms. In time, some of acute phase response biomarkers 
combinations might perhaps mature to FDA/EMEA-approvable IVD-tests, something 
costly and time-consuming (~10-20 years).   
As commented above, 12-95% of the quantitative variation in specific plasma protein levels 
depends on genetic background. Thus, haptoglobin shows a 20% CV intraindividual, and 
27.9% CV interindividual, and C-reactive protein 42.2% CV intraindividual and 92.5% CV 
interindividual (Anderson & Anderson, 2002). Polymorphic APPs, such as haptoglobin, 
alpha 2 HS glycoprotein, alpha 1 antitrypsin, vitamin D binding protein, and  transferrin, 
have been detected by proteomic techniques (2-DE) since the seventies (Anderson & 
Anderson, 1977; Goldman et al., 1985; Salgado et al, 2010). Some of these variations have 
been associated with several pathological conditions. For example, schizophrenia shows 
enhanced levels of haptoglobin (Table 5) and a significant association with the HP 1-2 
genotype (Wan et al., 2007), while the Hp 2-2 genotype seems rather linked to increased 
hemoglobin/haptoglobin/hemopexin content on HDL (ApoA1) particles and higher risk of 
coronary heart disease (Watanabe et al., 2009). It also has been found a higher susceptibility 
to chronic graft versus host disease (GVDH) after allogeneic hematopoietic cell 
transplantation (HSCT) in HP 2-2 patients (McGuirk et al., 2009). On the other hand, it was 
detected a higher incidence of myotrophic lateral sclerosis in vitamin D binding protein GC2 
isoform carriers (Palma et al., 2008). 
Post-translational modifications (PTMs) have also an important role in determining the 
function of proteins and come in a great degree of variation: citrullination, 
phosphorylation, proteolysis, glycosylation, oxidative modifications, etc. Many APPs 
show a complex combination of post-translational modifications, which may be disease- 
or inflammation-dependent. Thus, analysis of serum glycome in chronic inflammation 
associated to advanced ovarian cancer patients (Saldova et al., 2007) revealed sialyl 
Lewis x (SLex) structures in APPs that already had this marker: haptoglobin ┚-chain, 
alpha 1 acid glycoprotein, and alpha 1 antichymotrypsin. These glycosylation changes 
were parallel to the upregulation of these proteins (Amon et al., 2010; Lin et al, 2009) 
(Table 5), and could be tumour specific (Saldova et al., 2007). In addition, PTMs may 
have an impact on 2-DE patterns (Butler et al., 2003; Saldova et al., 2007), and 
application of lectin affinity chromatography prior 2-DE (or other proteomic 
techniques) could sometimes unmask previously unnoted expression changes 
(Seriramalu et al., 2010). Some of those pathological-dependent post-translational 
modifications in APPs may result in the generation of new antigens (neo-antigenicity), 
and hence autoantibodies against them (autoimmune diseases). Two good examples to 
illustrate this point are autoantibodies specific for citrullinated proteins in rheumatoid 
arthritis/multiple sclerosis and autoantibodies recognizing oxidatively modified C1q in 
rheumatoid arthritis and systemic erythematosus lupus (Eggleton, 2008). Similarly, 
phospholipids and apolipoproteins (e.g., ApoB100) of low-density lipoprotein (LDL) are 
also susceptible to oxidation, promoting chronic inflammation and the generation of 
autoantibodies against highly immunogenic oxidation-specific neoepitopes (Eggleton, 
2008).  
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Table 5. Acute phase protein patterns revealed by proteomic studies in different diseases.  
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Sometimes, different studies on a particular disease yield opposite data regarding the same 
acute phase reactant, and there are examples even within the same paper: e.g., alpha 2 
macroglobulin, inter--trypsin inhibitor in breast cancer, and transthyretin in severe acute 
respiratory syndrome. In the last case, this is due to different modulation of low a high 
molecular weight forms.  Abbreviations are the same as in Table 1. Blue colour indicates 
prototypical positive acute phase proteins, while yellow colour points out characteristic 
negative acute phase reactants. Proteomic methodologies used: Cardiovascular disease 
(Kim et al., 2011) 2-DE. Silver staining. MS/MS. Western blot. ELISA. Type 2 diabetes (Li et 
al., 2008) 1-DE/Coomassie. Rheumatoid arthritis (Salgado et al., 2010) HSA/Ig depleted 
sera. 2-DE/Coomassie. MS/MS ; (Doherty et al., 1998) whole plasma. 2-DE/Coomassie. 
Immunoassays; (Serada et al., 2010) Sera were depleted with MARS-Hu-14 (14 abundant 
proteins removed, Agilent Technologies), iTRAQ labelling. nanoLC-MS/MS. ELISA. 
Schizophrenia (Wan et al. 2007) 2-DE/Coomassie. MALDI-MS (PMF). Bipolar disorder 
(Sussulini et al., 2011) SELDI-TOF. Cystic fibrosis (Charro et al., 2011) Pooled serum 
samples processed with Multiple Affinity Removal System (MARS) spin cartridges (6 
abundant proteins removed ; Agilent Technologies). 2-DE/Coomassie. MALDI-TOF/TOF 
(MS/MS). Shotgun proteomics (nanoRPLC-MS/MS). Wilson disease (Park et al., 2009) Sera 
were depleted using MARS column (6 abundant proteins removed, Agilent Technologies). 
2-DE/Coomassie. MALDI-TOF (MS), MS/MS and Western blot. Severe acute respiratory 
syndrome (Chen et al., 2004) Unfractionated plasma samples. 2-DE/Sypro Ruby. MALDI-
TOF-MS and LC-MS/MS; (Wan et al., 2006) HSA/IgG depleted pooled plasma samples. 2-
DE DIGE. MALDI-MS/MS and Western blot. Allogeneic HSCT (Ryu et al., 2010) HSA/IgG 
depleted sera. 2-DE/silver staining. L-MS/MS. (McGuirk et al., 2010) HSA depleted sera. 2-
DE/Silver staining. LC-MS/MS. Down syndrome (Kolla et al., 2010) Plasma samples 
depleted with ProteoMiner Enrichment Kit (BioRad). Trypsin digestion, iTRAQ labelling, 
and SCX/Nano LC MALDI-TOF-TOF (MS/MS). Endometrial adenocarcinome (Abdul-
Rahman et al., 2007). Unfractionated sera, 2-DE/ Silver Stain/Coomassie. MALDI-MS (PMF 
and MS/MS). Western blot. Competitive ELISA. Squamous cell cervical carcinoma (Abdul-
Rahman et al., 2007). Unfractionated sera, 2-DE/ Silver Stain/Coomassie. MALDI-MS (PMF 
and MS/MS). Western blot. Competitive ELISA. Cervical adenocarcinoma (Abdul-Rahman 
et al., 2007). Unfractionated sera, 2-DE/ Silver Stain/Coomassie. MALDI-MS (PMF and 
MS/MS). Western blot. Competitive ELISA. Ovarian cancer (Amon et al., 2010) Serum 
samples were depleted using Multiple Affinity Removal System (MARS-7) columns 
(Agilent). 2D (Anion exchange/Reverse phase)-LC. MS/MS and ELISA. (Lin et al., 2009)  
Depleted sera (IgY12 columns). ICAT/LC/MS/MS and ELISA. (Boylan et al., 2010) 
Depleted sera (MARS and IgY12 columns). Trypsin digestion, iTRAQ labelling, and 
SCX/reverse phase LC/MS/MS. Western blot. Breast cancer (Kadowaki et al., 2011) MARS-
6 (Agilent) depleted sera. Reverse phase HPLC followed by 2-DE/Coomassie. Western blot 
and ELISA. Hepatocellular carcinoma (Yang et al., 2007) Serum samples. 2-DE/silver 
staining. Nano-HPLC-ESI-MS/MS. Lung adenocarcinoma (Hongsachart et al., 2009) Crude 
sera or WGA lectin-bound serum proteins. 2-DE/Sypro and 2-DE-DIGE. MALDI-TOF MS 
and MS/MS. Western blot.  
5. Conclusion  
The acute phase response is a highly conserved system that takes place during 
inflammation. During this response the serum levels of a continuously growing list of 
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plasma proteins change, either up- (some of them even 1000 fold) or downwards, under the 
influence of cytokines like IL-1, IL-6 or TNF. Some APPs have antiinflammatory effects 
(e.g., C-reactive protein, leptin), while others influence leukocyte activation/trafficking (e.g., 
serum amyloid A), modulate the coagulation/complement cascade (e.g., anti-thrombin 3, C-
reactive protein) or work for example as scavenger proteins (e.g., haptoglobin, serum 
amyloid A). With such a variety of functions, it is not surprising to find that some of these 
APPs are useful for diagnosis and prognosis of different diseases, and for that reason 
different companies have developed a high number of IVD tests based on single acute phase 
reactants. For example, amongst others, APPs-based tests are being used nowadays in 
hepatic/kidney function or nutritional status evaluation, to check the presence of infectious 
diseases, inflammation or autoimmune diseases, or to detect anemia or 
thrombofilia/bledding disorders. Apart from the discovery of new APPs whose potential 
clinical interest awaits future studies, some older ones seem to have got a second life as 
biomarkers, like C-reactive protein and cardiovascular risk assesment. In addition, the role 
of many of these APPs has not been completely elucidated (e.g., leucine rich 2 
glycoprotein, serum amyloid A), and experimental evidences also point out new 
associations of some of these proteins with different diseases, like for instance serum 
amyloid A and obesity-related disorders (e.g., cardiovascular diseases, atherosclerosis, 
diabetes, insulin resistence) (Zhao et al., 2010). Therefore, it can be said that much work 
remains to be done in the future around the acute phase reactants field. Actually, body fluid 
proteomics techniques have become promising tools to uncover new APPs and their 
associations with human disorders, and it is likely that some of these proteomic studies will 
finally reveal proteins within the expanding group of APPs with potential clinical interest. 
Moreover, these findings might even lead to the development and marketing of new IVD 
tests by the biotechnology industry. Nevertheless, according to data from different 
pathological scenarios, it is more likely that combinations of APPs will characterize disease 
states or predict disease outcomes better than single APPs. Thus, what the future may hold 
is the use of IVD assays with improved tests properties (e.g., sensitivity, specificity) based 
on disease-associated acute phase reactants patterns (or APPs “signatures”).  
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